U.S. Markets open in 7 hrs 26 mins

IPO Outlook For The Week: Biotechs, Dental Solutions And Digital Monitoring

Elizabeth Balboa

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not confirmed.

Envista Holdings Corp (NYSE: NVST) will issue nearly 26.77 million shares between $21 and $24 Wednesday on the New York Stock Exchange. The offering represents 17.3% of outstanding shares and is expected to raise about $738.8 million. Based in California, Envista equips dental professionals with technology and patient solutions through more than 30 brands.

IgM Biosciences, Inc. (NASDAQ: IGMS) will issue more than 7.8 million shares between $15 and $17 Wednesday on the Nasdaq. The offering represents 30.3% of outstanding shares and is expected to raise about $152.7 million. The California biotech company develops IgM antibodies for cancer therapies.

Datadog, Inc. (NASDAQ: DDOG) will issue 24 million shares between $19 and $22 Thursday on the Nasdaq. The offering represents 100% of outstanding shares and is expected to raise about $607.2 million. Datadog provides app monitoring and analytics for customers ranging from Whole Foods to Activision Blizzard, Inc. (NASDAQ: ATVI) to AARP.

Exagen Inc (NASDAQ: XGN) will issue more than 3.33 million shares between $14 and $16 Thursday on the Nasdaq. The offering represents 29.7% of outstanding shares and is expected to raise about $61.3 million. The commercial-stage life sciences company develops diagnostic, prognostic and monitoring products for the treatment of autoimmune conditions.

Ping Identity Holding Corp. (NYSE: PING) will issue 12.5 million shares between $14 and $16 Thursday on the New York Stock Exchange. The offering represents 16.1% of outstanding shares and is expected to raise about $230 million. Ping offers solutions to improve digital security, customer experience and tech management.

Related Links:

What Is Reg A+?

What Is A Lock-Up Expiration Date And Why Is It Important?

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.